Core Insights - Gyre Therapeutics announced positive results from its Phase 3 clinical trial of Hydronidone, an anti-fibrotic agent for liver fibrosis in chronic hepatitis B, to be presented at The Liver Meeting® 2025 [1][2] Company Overview - Gyre Therapeutics is a biopharmaceutical company based in San Diego, CA, focused on developing and commercializing Hydronidone for liver fibrosis, including MASH, in the United States [2] - The company leverages its experience in mechanistic studies and clinical trials related to CHB-induced liver fibrosis [2] - Gyre is also advancing a broad pipeline in China through its indirect controlling interest in Gyre Pharmaceuticals, which includes therapeutic expansions of ETUARY and development programs for F573, F528, and F230 [2] Clinical Trial Details - The Phase 3 trial results of Hydronidone will be presented by Prof. Lungen Lu, M.D., at The Liver Meeting® 2025 on November 7, 2025 [2] - The presentation is categorized under the Hepatitis B session and has been selected as a Poster of Distinction [2]
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025